According to the report, the heparin market is anticipated to grow from USD 9 Billion in 2025 to USD 16.6 Billion in 2035 at a CAGR of 6.3% during the forecast. Attributed to the growing numbers of cardiovascular and orthopedic surgeries occurring now and the increases in thrombotic disease, the heparin market is experiencing transformations. Manufacturers will continue to concentrate on developing low molecular weight heparin (LMWH) products that are safer for patients' results.
Additionally, with the growing collaborations with healthcare providers in emerging markets, healthcare providers hope to increase accessibility and affordability with anticoagulant therapy worldwide. Heparin has been under increased demand through new indications, and so companies will target innovations based on low molecular weight heparin and expand production to comply with the global requirements. Moreover, collaborations between pharmaceutical companies and hospitals in emerging markets, able to better the supply of medications, as well as, cost.
However, several challenges, including, the supply of raw materials, time consuming preclinical and regulatory processes, and the prevalence of counterfeit drugs will remain hurdles and inefficient for market growth. Current market intentions focus on alternative manufacturing processes, artificial, or synthetic alternatives, and ultimately, increased quality control for multinational compliance.
The heparin market is propelling ahead due to rising rates of cardiovascular disease and to the increasing use of heparin (as an anticoagulant) in a number of surgical and dialysis procedures, and the increasing demand for low molecular weight heparins (LMWHs) in both inpatient and outpatient therapeutic care protocols.
Supply chain challenges and contamination fears in the heparin marketplace have made some health care professionals concerned about the safety of heparin, and their fears have limited the use of heparin as a standard of care in the United States. The existence of competing anticoagulant drugs, dabigatran in particular, and side effects related to heparin; in particular bleeding or hemorrhage risks, limit the broad adoption of this product.
The concerning aspect is that the potential development of new synthetic and bioengineered heparins should translate into more safe and effective options for anticoagulant therapeutic options, and the expanded indications of heparin, including in oncology and other areas of therapeutics, will be a catalyst for both future growth and the decision-making process in the marketplace.
The heparin market is encountering major obstacles in light of global tariff policies, especially related to importing raw materials. Serving as a key supplier of heparin, China is subject to U.S. tariffs on heparin which are supposed to increase manufacturing costs and impact supply chains. Thus, if this occurs, then there is likely to be product supply shortages, and also some price fluctuations, which may adversely affect patients’ ability to obtain the medication.
Because of resulting delays, stakeholders are considering alternative sources and forms of production, such as bovine-derived heparin or domestic production capabilities. Considering which, any alternative source of heparin may not be scalable in a timely fashion or cost-competitive, which creates long-term strategic hurdles for the industry.
Key players in the global heparin market include prominent companies such as Aspen Pharmacare Holdings Limited, B. Braun Melsungen AG, Baxter International Inc., Bharat Serums and Vaccines Limited, Bioiberica S.A.U., Dr. Reddy’s Laboratories Ltd., Emcure Pharmaceuticals Ltd., Fresenius SE & Co. KGaA, Gland Pharma Limited, Hebei Changshan Biochemical Pharmaceutical Co., Ltd., Hikma Pharmaceuticals PLC, Leo Pharma A/S, Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd., Nichi-Iko Pharmaceutical Co., Ltd., Pfizer Inc., Pharma Action GmbH, Samarth Life Sciences Pvt. Ltd., Sanofi S.A., Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Teva Pharmaceutical Industries Ltd., and other key players, along with several other key players contributing to market growth through innovation, strategic partnerships, and global expansion.
MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.
We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.
800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.
+1(302)303-2617
3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.
Table of Contents
Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography
We will customise the research for you, in case the report listed above does not meet your requirements.
Get 10% Free Customisation